Children with CKD have a significant burden, including fatigue and sleep disturbances.

Published Date: 13 Mar 2023

A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...

Read Full News

Latest News

Deep Dive: The Evolving GLP-1 Class Overview

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

First-in-Class Drug Approved for IgA Nephropathy

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Navigating New Guidelines in IgA Nephropathy

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

Todays Updates

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

Todays Updates

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

Latest News

The GLP-1 class now spans ten products across six indications. This clinical deep dive maps the 2026 roster to help clinicians select the right agent for established CVD, CKD, MASH, or OSA.

Revealing CKD: Early Detection Strategies to Reduce Cardiorenal Risk

It has not been established whether atacicept slows kidney function decline long-term, however

Ushering in a New Era of IgAN Care: Targeted Therapies and Evolving Guidelines

Navigating New Guidelines in IgA Nephropathy

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

News All Time

APOL1 Gene and Focal Segmental Glomerulosclerosis

Genetic variants tied to increased risk are only found in those of African decent

Make the Diagnosis: Chest Pain, Dyspnea, Palpitations, and More: What’s Her Diagnosis?

A 45-year-old woman presented to the emergency department with complaints of chest pain, heart palpitations that developed earlier that day, and dyspnea that began 3 days prior and had progressed. Can you diagnose the patient?

Rewriting What We Know About Kidney Transplant Rejection

Rewriting What We Know About Kidney Transplant Rejection

First Oral Carbapenem Approved for Complicated UTIs

Tebipenem pivoxil proved noninferior to IV imipenem-cilastatin in hospitalized patients

How Did a Patient Survive a Decade With Metastatic RCC?

Surgery had beneficial role

360 Dead in Outbreak; McConnell Still Hospitalized? FDA Rejects Kidney Disease Drug

Health news and commentary gathered by MedPage Today staff

US FDA Declines to Approve Unicycive's Kidney Disease Drug

Unicycive Therapeutics said on Tuesday the U.S. drug regulator has declined to approve its drug to ⁠treat elevated phosphate levels in chronic kidney disease patients on...

The Chatbot Will See You Now: A Crisis in Trust?

When healthcare feels out of reach, Europe’s patients are turning to AI for answers — and sometimes for the confidence to medicate themselves.

Extended-Release Febuxostat Beats Standard Drug for Gout

A new 24-hour version of febuxostat lowers uric acid levels significantly better than the standard drug for patients with severe gout, though it may carry a higher risk of serious side effects.

Mineralys' Pill Cuts Blood Pressure in Kidney Disease Patients

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented ⁠at a major European...

Project Aims for Awareness of APOL1-Mediated Kidney Disease

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations and medical trainees.

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

APOL1-Mediated Kidney Disease: Managing Family Discussions, Testing, and Implications

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Navigating APOL1 Genetic Testing: Counseling Patients and Their Families

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Critical Bedside Moments in HRS-AKI: From Recognizing Risk to Treatment Initiation

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Changing the Course of HRS-AKI: Guideline-Directed Approaches to Optimize Treatment

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Entering a New Era of Opportunity for APOL1-Mediated Kidney Disease (AMKD): Connecting Genetic Screening to Clinical Trials for Breakthrough Therapies

Recommended News For You

New opportunities for screening and treatment have been created by the identification of the genetic drivers of esophageal cancer.

NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

Clinical trial is testing whether heavy lifting could combat cancer side effects

A study outlines the need for policies that enhance cancer patients' autonomy and information.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

Recommended Articles For You

Innovative Advances in Oncology for Specialists 

Revolutionizing Cancer Treatment with Mercaptopurine: A New Hope for Patients 

Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells 

Rehabilitation of Functional Capacity Following Cancer-Related Prolonged Deconditioning 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation

2.

Lower screening age calls for more tailored bowel cancer surveillance

3.

For relapsed or resistant DLBCL, odronextamab produced positive results.

4.

Booze and Pancreatic Cancer Risk; From 'Hospice' to 'Hope'; Gen Z-ers Skip Screening

5.

Study identifies new target for obesity-related breast cancer

1.

Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment

2.

Oncology Treatment: Innovations, Education, and Clinical Practice Insights

3.

Modern Oncology Education in the Era of Targeted Therapies

4.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

5.

Gene Therapy for Hemophilia: A New Hope on the Horizon

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

1.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

2.

Innovations in Hematology

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

4.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

5.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot